Localization of high affinity [3H]glibenclamide binding sites within the substantia nigra zona reticulata of the rat brain.
The rat substantia nigra zona reticulata contains a high density of binding sites for glibenclamide, an adenosine triphosphate-sensitive potassium channel inhibitor, but the precise location of glibenclamide binding sites within this area has not previously been examined. By combining neurochemical lesion and autoradiographical studies we have shown that high affinity [3H]glibenclamide binding sites are located on striatonigral terminals. Unilateral injections of 6-hydroxydopamine into the medial forebrain bundle or of quinolinic acid into the striatum were performed in anaesthetized adult rats to lesion the nigrostriatal and striatonigral pathways respectively. Autoradiography was performed on coronal sections of midbrain with [3H]glibenclamide, [3H]YM-09151-2 (dopamine D2 receptor antagonist) and [3H]SCH 23390 (dopamine D1 receptor antagonist) at three rostrocaudal levels of the substantia nigra. Under the conditions of the incubation [3H]glibenclamide binds primarily to the high affinity site. Following the 6-hydroxydopamine nigrostriatal lesion, D2 receptor binding was reduced (by up to 67%) on the lesioned side at all three levels of the substantia nigra whereas D1 receptor and glibenclamide binding were not significantly affected. In contrast, following striatonigral pathway lesion with quinolinic acid D2 receptor binding was unchanged on the lesioned side, but both D1 receptor and glibenclamide binding were reduced at all three levels (by up to 85% and 63% in the area of maximum lesion, respectively). In adjacent sections, the pattern of D1 binding loss was closely paralleled by the loss of glibenclamide binding. These results demonstrate that the high affinity glibenclamide binding sites of the substantia nigra zona reticulata are, at least in part, located on the terminals of striatonigral projection neurons.
Hicks
G A
GA
Department of Pharmacology, University of Bristol, School of Medical Sciences, U.K.
Hudson
A L
AL
Henderson
G
G
D000255:Adenosine Triphosphate / Q000502:physiology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects; D005905:Glyburide / Q000378:metabolism*; D008297:Male; D016627:Oxidopamine / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects*; D011485:Protein Binding; D017378:Quinolinic Acid / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011955:Receptors, Drug / Q000187:drug effects*; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*
D015221:Potassium Channels; D011955:Receptors, Drug; C067662:glibenclamide receptor; D016627:Oxidopamine; D000255:Adenosine Triphosphate; D017378:Quinolinic Acid; D005905:Glyburide